Crucell Holland B.v.

Stefan Kostense

Ronald Vogels

Maria Grazia Pau

Lennart Holterman

Mieke Caroline Sprangers

Menzo Jans Emco Havenga

Menzo Havenga

Menzo J E Havenga

Described are new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, also described are new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Settings for recombinant adenoviral-based vaccines

The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Described are of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, described are assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Growing community of inventors

The Hague, Netherlands

Stefan Kostense